No teratogenic effect after clotrimazole therapy during pregnancy.
We evaluated the potential teratogenic effects of vaginal and/or topical administration of clotrimazole in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities (1980-1992). The dataset included 18,515 case pregnancies and 32,804 control pregnancies; 7.1% of case and 7.7% of control women used clotrimazole during pregnancy. Clotrimazole use was not clearly associated with an increase in the total (fetal + birth) prevalence of any congenital abnormality group. There was, however, a suggestion that clotrimazole use was associated with a decrease in the prevalence of undescended testis (prevalence odds ratio = 0.72; 95% confidence interval = 0.54-0.95).
Department of Human Genetics and Teratology, National Institute of Public Health/World Health Organization Collaborating Centre for the Community Control of Hereditary Diseases, Budapest, Hungary.
A E
AE
Czeizel
M
M
Tóth
M
M
Rockenbauer
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology*; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D016022:Case-Control Studies; D003022:Clotrimazole / Q000627:therapeutic use*; D005260:Female; D005865:Gestational Age; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D016017:Odds Ratio; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*
D000935:Antifungal Agents; D003022:Clotrimazole